Jay D Kranzler bought $1,250 of ATXI
director at AVENUE THERAPEUTICS, INC.. 500 shares at an average of $2.50, traded Sep 27, 2024, filed Oct 1, 2024.
Score components
- +15RoleDirector
- 0Trade size$1k at market
- +10Relative to holdingsHoldings up 417%
- +8Price context95% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m 0.0%, 3m -16.7%, 6m -87.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-24-104931, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 27, 2024 | POpen-market purchase COMMON STOCK, PAR VALUE $0.0001 | +3 | $2.40 | $7 | 123 | Oct 1, 2024 |
| Sep 30, 2024 | POpen-market purchase COMMON STOCK, PAR VALUE $0.0001 | +497 | $2.50 | $1,243 | 620 | Oct 1, 2024 |
Related signals
Other insiders at AVENUE THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | ATXIsell AVENUE THERAPEUTICS, INC. | Neil Herskowitz director | $46 23 shares | -19% | |
| 15Weak | ATXIsell AVENUE THERAPEUTICS, INC. | Jay D Kranzler director | $137 61 shares | -10% | |
| 41Moderate | ATXIsell AVENUE THERAPEUTICS, INC. | Robert L Davidow owner | $87k 617,000 shares | -65% | |
| 57Moderate | ATXIsell AVENUE THERAPEUTICS, INC. | InvaGen Pharmaceuticals, Inc. owner | $3.0M 388,888 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.